FMP

FMP

Enter

CLRB - Cellectar Bioscience...

photo-url-https://images.financialmodelingprep.com/symbol/CLRB.png

Cellectar Biosciences, Inc.

CLRB

NASDAQ

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

0.271 USD

0.0065 (2.4%)

CLRB Financial Statements

Year

2024

2023

2022

2021

Current Assets

24.25M

10.45M

20.53M

36.57M

Cash & Short Term Investments

23.29M

9.56M

19.87M

35.7M

Cash And Cash Equivalents

23.29M

9.56M

19.87M

35.7M

Short Term Investments

0

0

0

0

Net Receivables

0

0

0

0

Inventory

0

0

0

0

Other Current Assets

961.66k

888.23k

663.24k

867.49k

Non-Current Assets

1.22M

1.62M

1.06M

630.35k

Property, Plant & Equipment

1.19M

1.59M

978.98k

549.13k

Goodwill And Intangible Assets

0

0

0

0

Goodwill

0

0

0

0

Intangible Assets

0

0

0

0

Long Term Investments

0

0

0

0

Tax Assets

0

0

0

0

Other Non-Current Assets

29.78k

29.78k

81.21k

81.21k

Other Assets

0

0

0

0

Total Assets

25.47M

12.08M

21.59M

37.2M

-

-

-

-

Current Liabilities

9.39M

25.36M

5.53M

3.99M

Accounts Payable

611k

5.62M

2.56M

1.42M

Short Term Debt

84.42k

0

50.85k

135.45k

Tax Payables

0

0

0

0

Deferred Revenue

0

0

0

2.44M

Other Current Liabilities

8.69M

18.19M

1.95M

368.46k

Total Current Liabilities

9.39M

25.36M

5.53M

3.99M

Total Non-Current Liabilities

1.79M

494k

552.98k

166.29k

Long-Term Debt

0

0

0

0

Deferred Revenue

0

0

0

0

Deferred Taxes Liabilities

0

0

0

0

Other Non Current liabilities

1.79M

0

0

0

Total Liabilities

11.18M

25.85M

6.08M

4.16M

Other Liabilities

0

0

0

0

Stockholders Equity

14.29M

-15.16M

15.51M

33.05M

Common Stock

461

207

94

611

Retained Earnings

-247.34M

-217.48M

-179.5M

-150.9M

Accumulated Other Comprehensive Income/Loss

0

0

0

0

Other Shareholders Equity

261.12M

13.34M

0

0

Total Liabilities and Stockholders Equity

25.47M

12.08M

21.59M

37.2M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-217.48M

-179.5M

-150.9M

-126.78M

Net Income

-44.58M

-37.98M

-28.6M

-23.97M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-247.34M

-217.48M

-179.5M

-150.9M

Other Distributions

-29.86M

-37.98M

-28.6M

-24.12M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

1.19M

1.59M

978.98k

549.13k

Annual Depreciation

0

192.38k

238.87k

227.64k

Capital Expenditure

-104.19k

-864.04k

-225.97k

-141.36k

Net PPE

1.3M

2.26M

966.08k

462.86k

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep